Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


26.08.2024

1 Am J Epidemiol
1 Arch Bronconeumol
2 BMC Cancer
1 Cancer Res
1 Chest
1 Clin Cancer Res
1 Clin Lung Cancer
3 Eur J Cancer
1 Hum Pathol
1 J Cancer Res Clin Oncol
1 J Clin Oncol
1 J Immunol
1 J Natl Cancer Inst
1 J Thorac Cardiovasc Surg
1 Lancet Oncol
2 Lung Cancer
1 Nat Med
1 Oncogene
1 Oncologist
2 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Epidemiol

  1. KEIL AP, Li Y, Lan Q, Bertke S, et al
    Inverse Probability Weighting to Estimate Impacts of Hypothetical Occupational Limits on Radon Exposure to Reduce Lung Cancer.
    Am J Epidemiol. 2024 Aug 21:kwae299. doi: 10.1093.
    PubMed         Abstract available


    Arch Bronconeumol

  2. XIE M, Lin X, Bao X, Liang Y, et al
    Tertiary Lymphoid Structure in Tumor Microenvironment and Immunotherapy of Lung Cancer.
    Arch Bronconeumol. 2024 Jul 27:S0300-2896(24)00285.
    PubMed         Abstract available


    BMC Cancer

  3. LUO LL, Cao Y, Zhang JJ, Xie YX, et al
    The role of tRF-Val-CAC-010 in lung adenocarcinoma: implications for tumorigenesis and metastasis.
    BMC Cancer. 2024;24:1033.
    PubMed         Abstract available

  4. HOSOYA K, Ozasa H, Tanji M, Yoshida H, et al
    Performance status improvement and advances in systemic treatment after brain metastases resection: a retrospective single-center cohort study of non-small cell lung cancer patients.
    BMC Cancer. 2024;24:1030.
    PubMed         Abstract available


    Cancer Res

  5. LIN W, Wang N, Wu S, Diao M, et al
    NUAK1-Mediated Phosphorylation of NADK Mitigates ROS Accumulation to Promote Osimertinib Resistance in Non-Small Cell Lung Carcinoma.
    Cancer Res. 2024 Aug 19. doi: 10.1158/0008-5472.CAN-24-0249.
    PubMed         Abstract available


    Chest

  6. FOX AH, Alexander M, Forcucci JA, Silvestri GA, et al
    Biomarker Testing for Guiding Precision Medicine for Patients with Non-Small Cell Lung Cancer.
    Chest. 2024 Aug 14:S0012-3692(24)04916-X. doi: 10.1016/j.chest.2024.
    PubMed         Abstract available


    Clin Cancer Res

  7. KOBAN MU, Hartmann M, Amexis G, Franco P, et al
    Targeted therapies, novel antibodies, and immunotherapies in advanced non-small cell lung cancer: clinical evidence and drug approval patterns.
    Clin Cancer Res. 2024 Aug 23. doi: 10.1158/1078-0432.CCR-24-0741.
    PubMed         Abstract available


    Clin Lung Cancer

  8. ACKER F, Klein A, Rasokat A, Eisert A, et al
    Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition.
    Clin Lung Cancer. 2024 Jul 23:S1525-7304(24)00151.
    PubMed         Abstract available


    Eur J Cancer

  9. LIU SY, Erazo T, Jee J, Arfe A, et al
    Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer.
    Eur J Cancer. 2024;210:114257.
    PubMed         Abstract available

  10. ZHU H, Wang FL, Liu JR
    Letter Re: Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
    Eur J Cancer. 2024 Aug 8:114267. doi: 10.1016/j.ejca.2024.114267.
    PubMed        

  11. FALCHERO L, Meyer N, Molinier O, Al Freijat F, et al
    Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting.
    Eur J Cancer. 2024;210:114277.
    PubMed         Abstract available


    Hum Pathol

  12. RERKPICHAISUTH V, Lau RP, Meyerson C, Fishbein GA, et al
    The utility of the lineage specific immunohistochemical stains SATB2, CDX2, and villin, and the mucin glycoproteins MUC2, MUC5AC, and MUC6 to distinguish pulmonary invasive mucinous adenocarcinoma from metastatic colorectal carcinoma.
    Hum Pathol. 2024;151:105627.
    PubMed         Abstract available


    J Cancer Res Clin Oncol

  13. UHLENBRUCH M, Kruger S
    Effect of TTF-1 expression on progression free survival of immunotherapy and chemo-/immunotherapy in patients with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2024;150:394.
    PubMed         Abstract available


    J Clin Oncol

  14. YANG JC, Lee DH, Lee JS, Fan Y, et al
    Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor?Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.
    J Clin Oncol. 2024 Aug 22:JCO2302747. doi: 10.1200/JCO.23.02747.
    PubMed         Abstract available


    J Immunol

  15. DIAMANTOPOULOS N, Li J, Bouchard A, Joumier L, et al
    ICOS-expressing Regulatory T Cells Influence the Composition of Antitumor CTL Populations.
    J Immunol. 2024;213:753-762.
    PubMed         Abstract available


    J Natl Cancer Inst

  16. LIU Q, Medina HN, Koru-Sengul T, Rodriguez E, et al
    Intra-Ethnic and Geographic Disparities in Stage at Diagnosis for Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2024 Aug 21:djae199. doi: 10.1093.
    PubMed         Abstract available


    J Thorac Cardiovasc Surg

  17. CHU NQ, Tan KS, Dycoco J, Adusumilli PS, et al
    Determinants of successful minimally invasive surgery (MIS) for resectable non-small cell lung cancer (NSCLC) after neoadjuvant therapy.
    J Thorac Cardiovasc Surg. 2024 Aug 19:S0022-5223(24)00696.
    PubMed         Abstract available


    Lancet Oncol

  18. ZHAO Y, He Y, Wang W, Cai Q, et al
    Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.
    Lancet Oncol. 2024 Aug 16:S1470-2045(24)00379.
    PubMed         Abstract available


    Lung Cancer

  19. MALHOTRA J, Chiappori A, Fujioka N, Hanna NH, et al
    Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study.
    Lung Cancer. 2024;195:107932.
    PubMed         Abstract available

  20. TASOUDIS P, Loufopoulos G, Manaki V, Doerr M, et al
    Long term outcomes after lobar versus sublobar resection for patients with Non-Small cell lung Cancer: Systematic review and individual patient data Meta-Analysis.
    Lung Cancer. 2024;195:107929.
    PubMed         Abstract available


    Nat Med

  21. ROBICHAUX JP, Elamin YY, Tan Z, Carter BW, et al
    Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
    Nat Med. 2024 Aug 20. doi: 10.1038/s41591-024-03178.
    PubMed        


    Oncogene

  22. NGUYEN A, Nunez CG, Tran TA, Girard L, et al
    Jumonji histone demethylases are therapeutic targets in small cell lung cancer.
    Oncogene. 2024 Aug 18. doi: 10.1038/s41388-024-03125.
    PubMed         Abstract available


    Oncologist

  23. BOULANGER MC, Schneider JL, Lin JJ
    Advances and future directions in ROS1 fusion-positive lung cancer.
    Oncologist. 2024 Aug 23:oyae205. doi: 10.1093.
    PubMed         Abstract available


    PLoS One

  24. ANANDAKRISHNAN R, Shahidi R, Dai A, Antony V, et al
    An approach for developing a blood-based screening panel for lung cancer based on clonal hematopoietic mutations.
    PLoS One. 2024;19:e0307232.
    PubMed         Abstract available

  25. MA Y, Li Z, Li D, Zheng B, et al
    G0 arrest gene patterns to predict the prognosis and drug sensitivity of patients with lung adenocarcinoma.
    PLoS One. 2024;19:e0309076.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.